LONDON–(BUSINESS WIRE)–#cannabinoids–Óskare Capital is proud to announce the launch of the primary ever SEIS and EIS fund concentrating on the Medical and Pharmaceutical Cannabis sector. Óskare Capital UK will advise the Fund which is managed by Sapphire Capital Partners LLP.

The MEDCAN Fund is the primary fund of its form and will put money into each early-stage UK firms and international firms which have the requisite operations inside the UK. The Fund goals to offer UK retail buyers with entry to a diversified portfolio of firms on this quickly rising sector.

The Enterprise Investment Scheme (EIS) and the Seed Enterprise Investment Scheme (SEIS) are UK authorities initiative schemes which encourage progress and improvement by granting non-public UK buyers important tax breaks when investing in qualifying early- stage firms.

Óskare Capital UK Director Oliver Lamb, notes, “We were motivated to set up the MEDCAN fund with Sapphire Capital Partners LLP given that around 40% of our European dealflow is coming from the UK, and the tax breaks investors can gain through the SEIS and EIS schemes are significant.”

The Fund workforce particularly targets main firms within the UK which have the potential to develop into international champions. Examples embrace life sciences firms, with robust IP, growing novel therapeutics (cannabinoids and different molecules) that concentrate on the endocannabinoid system (“ECS”).

Discovered in 1992, ECS is present in people and all vertebrate species, and is used because the physique’s solution to keep homeostasis and adapt to environmental stress and adjustments. Cannabinoids and different novel molecules can work together with the ECS serving to to deal with a variety of situations together with most cancers, ache administration, nervousness, epilepsy, sleep, despair, uncommon illnesses, ADHD and many extra.

The MEDCAN Fund can even be investing within the firms that type a part of the broader medical and pharmaceutical hashish ecosystem of companies and merchandise that help this fast-growing international market. The Fund already has a powerful pipeline of offers and will put money into start-ups throughout your complete worth chain (from Seed to Patient) however won’t put money into hashish manufacturing or leisure hashish.

One notable UK hashish firm that has gone on to develop into a world success story is GW Pharmaceuticals the producer of the FDA permitted cannabis-based medicine Epidiolex which was acquired by Jazz Pharmaceuticals for $7.2billion.

Óskare Capital UK Director Nicola Broughton, feedback, “Whilst GW is clearly an excellent example of a UK success story in the sector, we believe that there are opportunities in the market with stronger intellectual property which address far wider ranges of medical conditions that would result in even greater exits.”

Capital at Risk

ENDS

Editor’s Notes

About Óskare Capital

Óskare Capital UK Ltd is majority owned by ÓSKARE CAPITAL SAS which launched the Dublin based mostly Oskare Fund I ICAV, the primary AIFM and ESG suitable Venture Capital fund with an funding give attention to the identical sector, concentrating on European and remainder of world targets. www.oskarecapital.com

About Sapphire Capital Partners LLP
Sapphire Capital Partners LLP are a multi award-winning funding supervisor and consultancy based mostly in each London and Belfast. www.sapphirecapitalpartners.co.uk

Contacts

PRESS CONTACTS:

Katy Horrocks
Tel: 07725 218 579

Email: katy.horrocks@icloud.com

Oliver Lamb
Tel: 07900 904 532

Email: ollie@oskarecapital.com

Sapphire Capital Partners LLP
PRESS CONTACT:

Andrew Drylie
Tel: 07835 090 620

Email: andrew@sapphirecapitalpartners.co.uk

This post was initially printed on this site



Source link